Filing Overview
Registrant: Eliem Therapeutics, Inc. The request metadata identifies Climb Bio, Inc., but the filing names Eliem Therapeutics, Inc. as the registrant. The Form 8-K reports results of the company’s virtual 2022 Annual Meeting of Stockholders held on May 19, 2022. The report was signed and dated May 24, 2022.
Business and Financial Context
This filing concerns corporate governance matters under Item 5.07 and does not provide revenue, profitability, cash flow, margin, debt, liquidity, operating guidance, or other financial metrics.
Material Matters and Voting Results
Election of Class I Directors
Stockholders elected all three nominees to serve until the 2025 Annual Meeting and until their successors are elected and qualified.
| Director | Votes For | Votes Withheld | Broker Non-Votes |
|---|---|---|---|
| Robert Azelby | 20,565,991 | 2,231,598 | 1,346,296 |
| Judith Dunn | 20,570,020 | 2,227,569 | 1,346,296 |
| Adam Rosenberg | 20,383,841 | 2,413,748 | 1,346,296 |
Ratification of Independent Auditor
Stockholders ratified the Audit Committee’s selection of PricewaterhouseCoopers LLP as the company’s independent registered public accounting firm for the fiscal year ending December 31, 2022.
| Votes For | Votes Against | Abstentions | Broker Non-Votes |
|---|---|---|---|
| 24,137,141 | 4,086 | 2,658 | 0 |
Outlook, Risks, and Unusual Items
The filing contains no management guidance, business outlook, new contingencies, or material risk disclosures. The principal verification issue is the apparent mismatch between the requested company name, Climb Bio, Inc., and the filing registrant, Eliem Therapeutics, Inc.
Key Facts to Verify
- Confirm that Eliem Therapeutics, Inc. is the intended company and that the filing is not being attributed incorrectly to Climb Bio, Inc.
- Verify the three director elections and their terms through the company’s proxy statement or subsequent filings.
- Confirm PwC’s appointment as independent registered public accounting firm for the year ending December 31, 2022.
- Note that this 8-K contains no current-period financial statements or operating performance data.